New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
09:15 EDTCSCO, RGSE, XONE, VOXX, INCY, SRNE, PLUG, CLVS, KSS, BMY, AAP, LIQD, KND, GTIV, WMT, CAVM, AVGOOn The Fly: Pre-market Movers
HIGHER: Cisco (CSCO), up 8% after reporting better than expected third quarter results. Avago (AVGO) is also up 0.6% and Cavium (CAVM) is up 3% following Cisco's report... Gentiva Health (GTIV), up 60% after Kindred Healthcare (KND) proposes to acquire the company for $14.00 per share in cash and stock... Advance Auto Parts (AAP), up 3.3% after raising its outlook... Clovis (CLVS), up 7.7% after reporting drug data at ASCO conference... Plug Power (PLUG), up 2.4% following upgrade at Cowen. DOWN AFTER EARNINGS: Wal-Mart (WMT), down 2.9%... Kohl's (KSS), down 3.6%... ExOne (XONE), down 15%... Real Goods Solar (RGSE), down 13.7%. ALSO LOWER: Bristol-Myers (BMY), down 4% following downgrade at BMO Capital citing last nights' ASCO abstracts discussing disappointing Nivo-Yervfoy combination data... VOXX International (VOXX), down 25% after downgraded at B. Riley following worse than expected Q4 results... Sorrento Therapeutics (SRNE), down 21% after 4.765M share secondary stock offering priced at $5.25... Incyte (INCY), down 9.7% after an abstract regarding a Phase 2 study of its pancreatic cancer drug was posted at ASCO... Liquid Holdings (LIQD), down 43.5% after its 32M share secondary priced at $1.25.
News For CSCO;CAVM;WMT;GTIV;KND;LIQD;AAP;BMY;KSS;CLVS;PLUG;SRNE;INCY;VOXX;XONE;RGSE;AVGO From The Last 14 Days
Check below for free stories on CSCO;CAVM;WMT;GTIV;KND;LIQD;AAP;BMY;KSS;CLVS;PLUG;SRNE;INCY;VOXX;XONE;RGSE;AVGO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 9, 2014
09:30 EDTRGSERGS Energy downgraded at Cowen
Subscribe for More Information
08:21 EDTGTIVGentiva Health sees FY14 EPS 85c-$1.15, consensus 90c
Gentiva reaffirmed its full-year 2014 outlook. Net revenues are expected to be in the range of $1.9B-$2.1B, Adjusted EBITDA is expected to be in the range of $177M-$195M. FY14 revenue consensus $1.97B. Gentiva's 2014 outlook includes the full-year impact of its Harden acquisition and the final 2014 Medicare home health and hospice reimbursement rates issued by the Centers for Medicare and Medicaid Services (CMS). The 2014 outlook excludes any ongoing losses from closed locations as the operations are wound down.
08:19 EDTGTIVGentiva Health sees Q2 adjusted EPS from cont. ops 33c, consensus 22c
Gentiva Health said the company anticipates results from continuing operations for Q2 to be equal to or in excess of the following, net revenues of $496M, adjusted EBITDA of $52M. Q2 revenue consensus $492.46M. The company said, "Gentiva’s continued momentum in the second quarter of 2014 reflects the success of the changes and strategic investments the Company has made over the past year. We strongly believe that today’s announcement provides further evidence that Gentiva’s strategy to increase stockholder value is working, reinforcing that Kindred’s offer grossly undervalues Gentiva and is not in the best interest of Gentiva stockholders.”
08:17 EDTGTIV, KNDGentiva Health says Kindred Healthcare offer 'substantially undervalues' company
Subscribe for More Information
08:05 EDTXONEExOne stake by Novel Century a positive for shares, says FBR Capital
Subscribe for More Information
07:14 EDTCSCOTech Data announces U.S. distribution agreement with Cisco
Subscribe for More Information
06:34 EDTRGSERGS Energy downgraded to Market Perform from Outperform at Cowen
Subscribe for More Information
06:06 EDTWMTWal-Mart implied volatility of 11 at lower end of index mean range
Subscribe for More Information
05:35 EDTCAVMCavium initiated with an Outperform at Imperial Capital
Subscribe for More Information
July 8, 2014
11:53 EDTXONEOptions with increasing implied volatility
Options with increasing implied volatility: VJET XONE ARIA FTNT STX DAL PSEC SAN AMJ
11:48 EDTWMTCEO Bill Simon says Wal-Mart starting to see pockets of growth
Subscribe for More Information
07:45 EDTCSCOCisco still has room to run, says Cantor
Subscribe for More Information
07:34 EDTINCYIncyte achieves $25M milestone for approval of Jakavi in Japan
Incyte Corporation (INCY) has earned a $25M milestone payment from Novartis (NVS) in connection with the approval of Jakavi in Japan for the treatment of patients with myelofibrosis. Incyte will record this amount as contract revenue in the third quarter. Under the Incyte-Novartis Collaboration and License Agreement, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the United States as Jakafi. Novartis also continues to make progress in obtaining formal pricing and reimbursement approval for a third major European country and expects this to occur in the second half of 2014. Once achieved, Incyte will earn an additional $60M milestone payment.
07:32 EDTCSCOSemiconductor Equipment & Materials International to hold a conference
SEMICON West to be held in San Francisco on July 8-10.
07:20 EDTBMYBristol-Myers price target lowered to $55 from $62 at Leerink
Subscribe for More Information
07:17 EDTBMY, INCYLeerink raises immuno-oncology market forecast to $36B
Subscribe for More Information
07:12 EDTWMTWal-Mart exec says U.S. job recovery not prompting spending, Reuters says
Subscribe for More Information
06:28 EDTWMTWal-Mart embracing small store models, online strategies, WSJ reports
Subscribe for More Information
06:16 EDTWMTWal-Mart implied volatility of 11 at lower end of index mean range
Subscribe for More Information
06:10 EDTCSCOCisco to host conference call
Conference call to discuss disruptive trends in data networking will be held on July 10 at 11 am. Webcast Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use